Drug makers to face uphill battle over drug pricing

Published: 2010-04-09 07:00:00

Updated: 2010-04-09 07:00:00

A report, released by the Health Insurance Review Assessment and Service on April 6, will mostly affect the revenue of pharmaceutical firms that sell antihypertensive drugs.

Based on the previous report of Professor Kim Jin-hyun last February, the HIRAS report stated that the government agency...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK